vs

Side-by-side financial comparison of KELLY SERVICES INC (KELYA) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

KELLY SERVICES INC is the larger business by last-quarter revenue ($1.2B vs $622.0M, roughly 1.9× Royalty Pharma plc). On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -3.3%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -3.1%).

Kelly Services, Inc. is an American multinational office staffing company. The company places employees at all levels in various sectors including financial services, information technology, and law. Also, its professional services include human resource and management consulting, outsourcing, recruitment, career transition, and vendor management. Kelly Services was founded by William Russell Kelly in 1946 and is headquartered in Troy, Michigan.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

KELYA vs RPRX — Head-to-Head

Bigger by revenue
KELYA
KELYA
1.9× larger
KELYA
$1.2B
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+8.1% gap
RPRX
4.8%
-3.3%
KELYA
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-3.1%
KELYA

Income Statement — Q4 FY2024 vs Q4 FY2025

Metric
KELYA
KELYA
RPRX
RPRX
Revenue
$1.2B
$622.0M
Net Profit
$214.2M
Gross Margin
20.3%
Operating Margin
-4.8%
62.4%
Net Margin
34.4%
Revenue YoY
-3.3%
4.8%
Net Profit YoY
2.9%
EPS (diluted)
$-0.86
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KELYA
KELYA
RPRX
RPRX
Q4 25
$622.0M
Q3 25
$609.3M
Q2 25
$578.7M
Q1 25
$568.2M
Q4 24
$1.2B
$593.6M
Q3 24
$1.0B
$564.7M
Q2 24
$1.1B
$537.3M
Q1 24
$1.0B
$568.0M
Net Profit
KELYA
KELYA
RPRX
RPRX
Q4 25
$214.2M
Q3 25
$288.2M
Q2 25
$30.2M
Q1 25
$238.3M
Q4 24
$208.2M
Q3 24
$800.0K
$544.0M
Q2 24
$4.6M
$102.0M
Q1 24
$25.8M
$4.8M
Gross Margin
KELYA
KELYA
RPRX
RPRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
20.3%
Q3 24
21.4%
Q2 24
20.2%
Q1 24
19.7%
Operating Margin
KELYA
KELYA
RPRX
RPRX
Q4 25
62.4%
Q3 25
70.1%
Q2 25
36.3%
Q1 25
94.0%
Q4 24
-4.8%
60.9%
Q3 24
0.3%
Q2 24
1.2%
50.2%
Q1 24
2.6%
-13.0%
Net Margin
KELYA
KELYA
RPRX
RPRX
Q4 25
34.4%
Q3 25
47.3%
Q2 25
5.2%
Q1 25
41.9%
Q4 24
35.1%
Q3 24
0.1%
96.3%
Q2 24
0.4%
19.0%
Q1 24
2.5%
0.8%
EPS (diluted)
KELYA
KELYA
RPRX
RPRX
Q4 25
$0.49
Q3 25
$0.67
Q2 25
$0.07
Q1 25
$0.55
Q4 24
$-0.86
$0.46
Q3 24
$0.02
$1.21
Q2 24
$0.12
$0.23
Q1 24
$0.70
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KELYA
KELYA
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$39.0M
$618.7M
Total DebtLower is stronger
$239.4M
$9.0B
Stockholders' EquityBook value
$1.2B
$9.7B
Total Assets
$2.6B
$19.6B
Debt / EquityLower = less leverage
0.19×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KELYA
KELYA
RPRX
RPRX
Q4 25
$618.7M
Q3 25
$938.9M
Q2 25
$631.9M
Q1 25
$1.1B
Q4 24
$39.0M
$929.0M
Q3 24
$32.8M
$950.1M
Q2 24
$38.2M
$1.8B
Q1 24
$200.7M
$843.0M
Total Debt
KELYA
KELYA
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$239.4M
$7.6B
Q3 24
$228.2M
$7.6B
Q2 24
$210.4M
$7.6B
Q1 24
$6.1B
Stockholders' Equity
KELYA
KELYA
RPRX
RPRX
Q4 25
$9.7B
Q3 25
$9.6B
Q2 25
$9.5B
Q1 25
$9.8B
Q4 24
$1.2B
$10.3B
Q3 24
$1.3B
$10.3B
Q2 24
$1.3B
$9.8B
Q1 24
$1.3B
$9.9B
Total Assets
KELYA
KELYA
RPRX
RPRX
Q4 25
$19.6B
Q3 25
$19.3B
Q2 25
$18.3B
Q1 25
$17.6B
Q4 24
$2.6B
$18.2B
Q3 24
$2.7B
$18.0B
Q2 24
$2.6B
$17.7B
Q1 24
$2.4B
$16.1B
Debt / Equity
KELYA
KELYA
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.19×
0.74×
Q3 24
0.18×
0.74×
Q2 24
0.16×
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KELYA
KELYA
RPRX
RPRX
Operating Cash FlowLast quarter
$15.0M
$827.1M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
1.1%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters
$15.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KELYA
KELYA
RPRX
RPRX
Q4 25
$827.1M
Q3 25
$702.6M
Q2 25
$364.0M
Q1 25
$596.1M
Q4 24
$15.0M
$742.5M
Q3 24
$-20.3M
$703.6M
Q2 24
$57.7M
$658.2M
Q1 24
$-25.5M
$664.6M
Free Cash Flow
KELYA
KELYA
RPRX
RPRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$13.0M
Q3 24
$-22.7M
Q2 24
$54.7M
Q1 24
$-29.2M
FCF Margin
KELYA
KELYA
RPRX
RPRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.1%
Q3 24
-2.2%
Q2 24
5.2%
Q1 24
-2.8%
Capex Intensity
KELYA
KELYA
RPRX
RPRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.2%
Q3 24
0.2%
Q2 24
0.3%
Q1 24
0.4%
Cash Conversion
KELYA
KELYA
RPRX
RPRX
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
2.50×
Q4 24
3.57×
Q3 24
-25.38×
1.29×
Q2 24
12.54×
6.45×
Q1 24
-0.99×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KELYA
KELYA

Science Engineering Technology$295.8M25%
Education$293.1M25%
Staffing Services$237.7M20%
Other$138.8M12%
Talent Solutions$120.5M10%
Outcome Based Services$103.6M9%
Permanent Placement$1.6M0%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons